Aurobindo Pharma Ltd. Investor Presentation

Aurobindo Pharma Ltd. Investor Presentation: Get insights into company performance, financials, capex plans and more

announcement
Conference/Earnings Calls Alerts
1094.05
-1.02%
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Investor Presentation
BSE India
Please refer to our letter dated August 10, 2020 wherein we have intimated the schedule of Investors/ Analysts call on August 13, 2020. In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Un-audited Financial Results of the Company for the first Quarter ended June 30, 2020. The presentation is also being uploaded in the following weblink of the Company. https://www.aurobindo.com/investors/results-reports-presentations/investor-presentations/
1094.05
-1.02%
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Investor Presentation
BSE India
Please refer to our letter dated June 1, 2020 wherein we have intimated the schedule of Investors/ Analysts call on June 4, 2020. In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Audited Financial Results of the Company for the fourth Quarter and year ended March 31, 2020. The presentation is also being uploaded in the following weblink of the Company. https://www.aurobindo.com/investors/results-reports-presentations/investor-presentations/
1094.05
-1.02%
AUROBINDO PHARMA LTD. - 524804 - Announcement under Regulation 30 (LODR)-Investor Presentation
BSE India
Please refer to our letter dated February 3, 2020 wherein we have intimated the schedule of Investors/ Analysts call on February 7, 2020. In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Un-audited Financial Results of the Company for the third Quarter and nine months period ended December 31, 2019. The presentation is also being uploaded in the following weblink of the Company. https://www.aurobindo.com/investors/results-reports-presentations/investor-presentations/
1094.05
-1.02%
AUROBINDO PHARMA LTD. - 524804 - Investor / Analysts Presentation
BSE India
Please refer to our letter dated November 8, 2019 wherein we have intimated the schedule of Investors/ Analysts call on November 13, 2019. In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Un-audited Financial Results of the Company for the second Quarter and half year ended September 30, 2019. The presentation is also being uploaded in the following weblink. https://www.aurobindo.com/investors/results-reports-presentations/investor-presentations/
1094.05
-1.02%
Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Investor Presentation
BSE India
Please refer to our letter dated August 5, 2019 wherein we have intimated the schedule of Investors/ Analysts call on August 8, 2019. In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Un-audited Financial Results of the Company for the first Quarter ended June 30, 2019. https://www.aurobindo.com/investors/results-reports-presentations/investor-presentations/
1094.05
-1.02%
Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Investor Presentation
BSE India
Please refer to our letter dated May 24, 2019, wherein we have intimated the schedule of Investors/ Analysts call on May 29, 2019. In this connection, we enclose herewith the presentation on the Audited Financial Results of the Company for the financial year ended March 31, 2019. The presentation is also being uploaded on the website of the Company - https://www.aurobindo.com/investors/results-reports-presentations/investor-presentations/
1094.05
-1.02%
Aurobindo Pharma Ltd - 524804 - Announcement under Regulation 30 (LODR)-Investor Presentation
BSE India
Please refer to our letter dated 5th February, 2019 wherein we have intimated the schedule of Investors/ Analysts call on February 8, 2019. In this connection, we enclose herewith the presentation that would be used in the Investors / Analysts call on the Un-audited Financial Results of the Company for the third Quarter and nine months period ended December 31, 2018. https://www.aurobindo.com/investors/results-reports-presentations/investor-presentations/
1094.05
-1.02%
Announcement under Regulation 30 (LODR)-Investor Presentation
BSE India
Please refer to our letter dated 9th November, 2018 wherein we have intimated the schedule of Investors/Analysts call on 13th November, 2018. In this connection, we enclose herewith the presentation that would be used in the Investors/Analysts call on the Unaudited Financial Results of the Company for the second quarter and half year ended 30th September, 2018....
1094.05
-1.02%
Announcement under Regulation 30 (LODR)-Investor Presentation
BSE India
Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we inform you that a conference call on acquisition of Sandoz's dermatology and oral solids businesses is scheduled on 6th September 2018 at 5:30 PM Please find attached the dial-in details of the call. In this connection, we enclose herewith the presentation that would be used in the aforesaid conference call....
1094.05
-1.02%
Announcement under Regulation 30 (LODR)-Investor Presentation
BSE India
Please refer to our letter dated 7th August, 2018 wherein we have intimated the schedule of Investors/Analysts call on 10th August, 2018. In this connection, we enclose herewith the presentation that would be used in the Investors/Analysts call on the Unaudited Financial Results of the Company for the first quarter ended 30th June, 2018. The presentation is also being uploaded on the website of the Company - http://www.aurobindo.com/investor-relations/investors/investor-presentation...

No results found